Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avalo Therapeutics, Inc.AVTX · Entity 4936 | Chief Medical Officer | December 10, 2021 | December 14, 2021 |
| Zyla Life SciencesZCOR · Entity 148990 | SVP and Chief Medical Officer | July 01, 2019 | July 01, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avalo Therapeutics, Inc.
Report date December 10, 2021 · Filed December 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,373 |
Reported balance
After 2021-12-10 transaction · row 1
1 source rowRow 1 · 2021-12-10 · Purchase · Acquired 6,371 · Balance 33,373 F1: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan.
Zyla Life Sciences
Report date July 01, 2019 · Filed July 01, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 190,000 |
Reported balance
After 2019-07-01 transaction · row 1
1 source rowRow 1 · 2019-07-01 · Grant · Acquired 190,000 · Balance 190,000 F1: Represents restricted stock units, which vest in three equal annual installments on the first three anniversaries of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units, which vest in three equal annual installments on the first three anniversaries of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 10, 2021 Filed Dec 14, 2021 18:19 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 6,371 | $1.57 | $10,002.47 |
DisclosureSEC source: 0001879785-21-000041 · edgar.xml · nonDerivative · entry 1 Wilkins H Jeffrey · CIK 0001779160 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,373 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 17:00 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | PurchaseCommon Stock | 912 | $2.28 | $2,079.36 |
DisclosureSEC source: 0001192482-21-000498 · edgar.xml · nonDerivative · entry 1 Wilkins H Jeffrey · CIK 0001779160 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,002 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document |
| July 01, 2019 Filed Jul 1, 2019 21:13 UTC | Zyla Life Sciences ZCOR · Entity 148990 | GrantCommon Stock | 190,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-008269 · edgar.xml · nonDerivative · entry 1 Wilkins H Jeffrey · CIK 0001779160 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 F1 · shares: Represents restricted stock units, which vest in three equal annual installments on the first three anniversaries of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.